Hepatitis B e-antigen negative chronic hepatitis B. (Q35020821)

5 August 2017

1 reference

title

Hepatitis B e-antigen negative chronic hepatitis B. (English)

1 reference

5 August 2017

1 reference

1 reference

Sarin SK

1

1 reference

5 August 2017

Satapathy SK

series ordinal

2

1 reference

5 August 2017

Chauhan R

series ordinal

3

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Journal of Gastroenterology and Hepatology

5 August 2017

published in

1 reference

5 August 2017

volume

17 Suppl 3

1 reference

5 August 2017

page(s)

S311-21

1 reference

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Clinical relevance of hepatitis B viral mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Vertical transmission of hepatitis B virus despite maternal lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Treatment with low-dose interferon-alpha in Bulgarian HBeAg-negative patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Diagnosis and management of pre-core mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Randomised controlled trial of recombinant human interferon -alpha A for chronic active hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.20.X

10.1046/J.1440-1746.17.S3.20.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference